Pridinol HCl | CAS# 968-58-1 | muscle relaxant

MedKoo Cat#: 414756 | Name: Pridinol HCl

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pridinol is a centrally acting anticholinergic agent primarily used as a muscle relaxant in the treatment of muscle spasms and related pain. Its bioactivity is largely attributed to its antagonistic effect on muscarinic acetylcholine receptors (mAChRs), particularly M1 and M2 subtypes, with reported Ki values in the micromolar range (e.g., ~3–10 µM depending on assay conditions and receptor subtype). This blockade reduces parasympathetic nervous system activity, leading to muscle relaxation and sedation. In vitro studies demonstrate its inhibition of acetylcholine-induced contractions in smooth muscle tissues, while in vivo, it exhibits dose-dependent muscle relaxant and antispasmodic effects in animal models.

Chemical Structure

Pridinol HCl

CAS#968-58-1 (HCl)

Theoretical Analysis

MedKoo Cat#: 414756

Name: Pridinol HCl

CAS#: 968-58-1 (HCl)

Chemical Formula: C20H26ClNO

Exact Mass: 331.1703

Molecular Weight: 331.88

Elemental Analysis: C, 72.38; H, 7.90; Cl, 10.68; N, 4.22; O, 4.82

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 750.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

968-58-1 (HCl) 511-45-5 (free base) 6856-31-1 (mesylate)

Synonym

Pridinol hydrochloride; Pridinol HCl

IUPAC/Chemical Name

1-Piperidinepropanol, alpha,alpha-diphenyl-, hydrochloride

InChi Key

IECCHUISCGCKKS-UHFFFAOYSA-N

InChi Code

InChI=1S/C20H25NO.ClH/c22-20(18-10-4-1-5-11-18,19-12-6-2-7-13-19)14-17-21-15-8-3-9-16-21;/h1-2,4-7,10-13,22H,3,8-9,14-17H2;1H

SMILES Code

OC(C1=CC=CC=C1)(C2=CC=CC=C2)CCN3CCCCC3.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 331.88 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Lauricella L, Calabrese N, Scaturro D, Migliorino D, Vecchio M, Letizia Mauro G. Effectiveness rehabilitative therapy and Pridinol Mesylate in low back pain. Front Med (Lausanne). 2025 Jan 22;11:1470996. doi: 10.3389/fmed.2024.1470996. PMID: 39911667; PMCID: PMC11794184. 2: Rodríguez-Basso ÁG, Bonafede SL, Prado HJ. Concurrent Determination of Pridinol, Diclofenac and Impurity A by HPLC-UV. J Chromatogr Sci. 2023 Dec 30;62(1):92-99. doi: 10.1093/chromsci/bmad017. PMID: 36912069. 3: Coyle S. Pridinol for cancer-related myofascial pain. BMJ Support Palliat Care. 2024 Jan 8;13(e3):e945-e947. doi: 10.1136/spcare-2022-003821. PMID: 36100426. 4: Überall MA, Müller-Schwefe GHH, Horlemann J. Efficacy and tolerability of the antispasmodic, pridinol, in patients with muscle-pain - results of primepain, a retrospective analysis of open-label real-world data provided by the German pain E-registry. Curr Med Res Opin. 2022 Jul;38(7):1203-1217. doi: 10.1080/03007995.2022.2077579. Epub 2022 Jun 1. PMID: 35575167. 5: Überall MA, Essner U, Müller-Schwefe GHH. Efficacy and safety/tolerability of pridinol: a meta-analysis of double-blind, randomized, placebo-controlled trials in adult patients with muscle pain. Curr Med Res Opin. 2022 Jul;38(7):1141-1151. doi: 10.1080/03007995.2022.2072089. Epub 2022 May 23. PMID: 35502575. 6: Richter M, Donath F, Wedemeyer RS, Warnke A, Horstmann A, Peschel C. Pharmacokinetics of oral pridinol: Results of a randomized, crossover bioequivalence trial in healthy subjects. Int J Clin Pharmacol Ther. 2021 Jun;59(6):471-477. doi: 10.5414/CP203900. PMID: 33835016; PMCID: PMC8167741. 7: Salazar-Rojas D, Intilangelo A, Vignaduzzo SE, Maggio RM. Development and validation of a green method for dissolution monitoring of pharmaceutical combinations. Meloxican and pridinol. J Pharm Biomed Anal. 2019 Jun 5;170:228-233. doi: 10.1016/j.jpba.2019.03.038. Epub 2019 Mar 18. PMID: 30933898. 8: Gaztañaga P, Baggio R, Vega DR. A crystallographic and thermal study of pridinol mesylate and its monohydrated solvate. Acta Crystallogr B Struct Sci Cryst Eng Mater. 2018 Jun 1;74(Pt 3):304-310. doi: 10.1107/S2052520618007023. Epub 2018 May 23. PMID: 29927393. 9: Simionato LD, Ferello L, Stamer S, Zubata PD, Segall AI. Validation of simultaneous volumetric and HPLC methods for the determination of pridinol mesylate in raw material. ISRN Pharm. 2013 Oct 2;2013:540676. doi: 10.1155/2013/540676. PMID: 24224103; PMCID: PMC3809392. 10: Vignaduzzo SE, Castellano PM, Kaufman TS. Development and validation of a dissolution test for meloxicam and pridinol mesylate from combined tablet formulation. Indian J Pharm Sci. 2010 Mar;72(2):197-203. doi: 10.4103/0250-474X.65033. PMID: 20838523; PMCID: PMC2929778. 11: Bianchini RM, Castellano PM, Kaufman TS. Development and validation of an HPLC method for the determination of process-related impurities in pridinol mesylate, employing experimental designs. Anal Chim Acta. 2009 Nov 10;654(2):141-7. doi: 10.1016/j.aca.2009.09.022. Epub 2009 Sep 20. PMID: 19854345. 12: Bianchini RM, Castellano PM, Kaufman TS. Validated stability-indicating HPLC method for the determination of pridinol mesylate. Kinetics study of its degradation in acid medium. J Pharm Biomed Anal. 2008 Dec 1;48(4):1151-60. doi: 10.1016/j.jpba.2008.09.005. Epub 2008 Sep 9. PMID: 18922659. 13: Vignaduzzo SE, Castellano PM, Kaufman TS. Method development and validation for the simultaneous determination of meloxicam and pridinol mesylate using RP- HPLC and its application in drug formulations. J Pharm Biomed Anal. 2008 Jan 22;46(2):219-25. doi: 10.1016/j.jpba.2007.09.011. Epub 2007 Sep 15. PMID: 17961953. 14: Vantaggiato DR, De Giovanni N. Suicide by multidrug ingestion: hypothesis on the role played by the self-administration of activated charcoal. Am J Forensic Med Pathol. 2007 Mar;28(1):55-8. doi: 10.1097/01.paf.0000257424.07395.b0. PMID: 17325466. 15: Zhao X, You T, Liu J, Sun X, Yan J, Yang X, Wang E. Drug-human serum albumin binding studied by capillary electrophoresis with electrochemiluminescence detection. Electrophoresis. 2004 Oct;25(20):3422-6. doi: 10.1002/elps.200305930. PMID: 15490448. 16: Svensson P, Wang K, Arendt-Nielsen L. Effect of muscle relaxants on experimental jaw-muscle pain and jaw-stretch reflexes: a double-blind and placebo-controlled trial. Eur J Pain. 2003;7(5):449-56. doi: 10.1016/S1090-3801(03)00013-2. PMID: 12935797. 17: Bastigkeit M. Kein Natrium--kein Schmerz. Neue Leitlinien bei Skelett- und Muskelschmerzen [No sodium--no pain. New guidelines in bone and muscle pain]. MMW Fortschr Med. 2000 Mar 30;142(13):50-1. German. PMID: 10783627. 18: Waelbroeck M, Camus J, Tastenoy M, Lambrecht G, Mutschler E, Kropfgans M, Sperlich J, Wiesenberger F, Tacke R, Christophe J. Thermodynamics of antagonist binding to rat muscarinic M2 receptors: antimuscarinics of the pridinol, sila- pridinol, diphenidol and sila-diphenidol type. Br J Pharmacol. 1993 Jun;109(2):360-70. doi: 10.1111/j.1476-5381.1993.tb13578.x. PMID: 8102927; PMCID: PMC2175680. 19: Zebrowska-Lupina I, Porowska A. Anticataleptic effect of taurine: interaction with antiparkinsonian agents. Pol J Pharmacol Pharm. 1987 Jul- Aug;39(4):329-35. PMID: 2897118. 20: Susman VL, Addonizio G. Assessing treatment of neuroleptic malignant syndrome. Am J Psychiatry. 1986 Jan;143(1):120-1. doi: 10.1176/ajp.143.1.aj1431120. PMID: 3942270.